{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:58:53Z","timestamp":1763765933077},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,7,27]],"date-time":"2012-07-27T00:00:00Z","timestamp":1343347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s12094-012-0856-5","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T08:21:57Z","timestamp":1343290917000},"page":"726-739","source":"Crossref","is-referenced-by-count":21,"title":["Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)"],"prefix":"10.1007","volume":"14","author":[{"given":"Pilar","family":"Garc\u00eda-Alfonso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Garc\u00eda-Foncillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Musul\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Garc\u00eda-Carbonero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artemio","family":"Pay\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"P\u00e9rez-Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Ram\u00f3n y Cajal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,27]]},"reference":[{"key":"856_CR1","doi-asserted-by":"crossref","unstructured":"American Gastroenterological Association (2001) American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology 121:195\u2013197","DOI":"10.1053\/gast.2001.25580"},{"key":"856_CR2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0016-5085(99)70510-X","volume":"116","author":"HF Vasen","year":"1999","unstructured":"Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453\u20131456","journal-title":"Gastroenterology"},{"key":"856_CR3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra012242","volume":"348","author":"HT Lynch","year":"2003","unstructured":"Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919\u2013932","journal-title":"N Engl J Med"},{"key":"856_CR4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djh034","volume":"96","author":"A Umar","year":"2004","unstructured":"Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261\u2013268","journal-title":"J Natl Cancer Inst"},{"key":"856_CR5","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jama.296.12.1469","volume":"296","author":"J Balmana","year":"2006","unstructured":"Balmana J, Stockwell DH, Steyerberg EW et al (2006) Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 296:1469\u20131478","journal-title":"JAMA"},{"key":"856_CR6","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.ejca.2005.04.039","volume":"41","author":"S Popat","year":"2005","unstructured":"Popat S, Houlston RS (2005) A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 41:2060\u20132070","journal-title":"Eur J Cancer"},{"key":"856_CR7","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJM199612053352303","volume":"335","author":"D Shibata","year":"1996","unstructured":"Shibata D, Reale MA, Lavin P et al (1996) The DCC protein and prognosis in colorectal cancer. N Engl J Med 335:1727\u20131732","journal-title":"N Engl J Med"},{"key":"856_CR8","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1078-0432.CCR-04-1458","volume":"11","author":"H Alazzouzi","year":"2005","unstructured":"Alazzouzi H, Alhopuro P, Salovaara R et al (2005) SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 11:2606\u20132611","journal-title":"Clin Cancer Res"},{"key":"856_CR9","first-page":"4002","volume":"27","author":"AD Roth","year":"2009","unstructured":"Roth AD, Tejpar S, Yan P et al (2009) Stage-specific prognostic value of molecular markers in colon cancer: results of the translational study on the PETACC 3\u2013EORTC 40993\u2013SAKK 60-00 trial. ASCO Meeting Abstracts 27:4002","journal-title":"ASCO Meeting Abstracts"},{"key":"856_CR10","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1200\/JCO.2008.18.6544","volume":"27","author":"S Ogino","year":"2009","unstructured":"Ogino S, Nosho K, Kirkner GJ et al (2009) PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 27:1477\u20131484","journal-title":"J Clin Oncol"},{"key":"856_CR11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.2005.01.086","volume":"23","author":"S Popat","year":"2005","unstructured":"Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609\u2013618","journal-title":"J Clin Oncol"},{"key":"856_CR12","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","volume":"28","author":"DJ Sargent","year":"2010","unstructured":"Sargent DJ, Marsoni S, Monges G et al (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219\u20133226","journal-title":"J Clin Oncol"},{"key":"856_CR13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1200\/JCO.2010.30.1366","volume":"29","author":"G Hutchins","year":"2011","unstructured":"Hutchins G, Southward K, Handley K et al (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29:1261\u20131270","journal-title":"J Clin Oncol"},{"key":"856_CR14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jnci\/djr153","volume":"103","author":"FA Sinicrope","year":"2011","unstructured":"Sinicrope FA, Foster NR, Thibodeau SN et al (2011) DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103:863\u2013875","journal-title":"J Natl Cancer Inst"},{"key":"856_CR15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jnci\/djr170","volume":"103","author":"S Tejpar","year":"2011","unstructured":"Tejpar S, Saridaki Z, Delorenzi M et al (2011) Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. J Natl Cancer Inst 103:841\u2013844","journal-title":"J Natl Cancer Inst"},{"key":"856_CR16","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/sj.onc.1207262","volume":"23","author":"F Bertucci","year":"2004","unstructured":"Bertucci F, Salas S, Eysteries S et al (2004) Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23:1377\u20131391","journal-title":"Oncogene"},{"key":"856_CR17","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2004.08.186","volume":"22","author":"Y Wang","year":"2004","unstructured":"Wang Y, Jatkoe T, Zhang Y et al (2004) Gene expression profiles and molecular markers to predict recurrence of Dukes\u2019 B colon cancer. J Clin Oncol 22:1564\u20131571","journal-title":"J Clin Oncol"},{"key":"856_CR18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jss.2004.10.009","volume":"124","author":"K Komuro","year":"2005","unstructured":"Komuro K, Tada M, Tamoto E et al (2005) Right- and left-sided colorectal cancers display distinct expression profiles and the anatomical stratification allows a high accuracy prediction of lymph node metastasis. J Surg Res 124:216\u2013224","journal-title":"J Surg Res"},{"key":"856_CR19","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1200\/JCO.2005.00.695","volume":"23","author":"S Eschrich","year":"2005","unstructured":"Eschrich S, Yang I, Bloom G et al (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23:3526\u20133535","journal-title":"J Clin Oncol"},{"key":"856_CR20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cncr.21170","volume":"104","author":"RS Croner","year":"2005","unstructured":"Croner RS, Peters A, Brueckl WM et al (2005) Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. Cancer 104:395\u2013404","journal-title":"Cancer"},{"key":"856_CR21","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1200\/JCO.2005.05.0229","volume":"24","author":"A Barrier","year":"2006","unstructured":"Barrier A, Boelle PY, Roser F et al (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24:4685\u20134691","journal-title":"J Clin Oncol"},{"key":"856_CR22","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1038\/sj.onc.1210060","volume":"26","author":"A Barrier","year":"2007","unstructured":"Barrier A, Roser F, Boelle PY et al (2007) Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 26:2642\u20132648","journal-title":"Oncogene"},{"key":"856_CR23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-05-2734","volume":"13","author":"YH Lin","year":"2007","unstructured":"Lin YH, Friederichs J, Black MA et al (2007) Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res 13:498\u2013507","journal-title":"Clin Cancer Res"},{"key":"856_CR24","first-page":"1099","volume":"30","author":"E Vendrell","year":"2007","unstructured":"Vendrell E, Ribas M, Valls J et al (2007) Genomic and transcriptomic prognostic factors in R0 Dukes B and C colorectal cancer patients. Int J Oncol 30:1099\u20131107","journal-title":"Int J Oncol"},{"key":"856_CR25","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1200\/JCO.2010.28.9538","volume":"28","author":"MJ O\u2019Connell","year":"2010","unstructured":"O\u2019Connell MJ, Lavery I, Yothers G et al (2010) Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II\/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 28:3937\u20133944","journal-title":"J Clin Oncol"},{"key":"856_CR26","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1200\/JCO.2010.32.8732","volume":"29","author":"RG Gray","year":"2011","unstructured":"Gray RG, Quirke P, Handley K et al (2011) Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 29:4611\u20134619","journal-title":"J Clin Oncol"},{"key":"856_CR27","first-page":"4036","volume":"27","author":"AM Glas","year":"2009","unstructured":"Glas AM, Roepman P, Salazar R et al (2009) Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients. ASCO Meet Abstr 27:4036","journal-title":"ASCO Meet Abstr"},{"key":"856_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2010.30.1077","volume":"29","author":"R Salazar","year":"2011","unstructured":"Salazar R, Roepman P, Capella G et al (2011) Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29:17\u201324","journal-title":"J Clin Oncol"},{"key":"856_CR29","doi-asserted-by":"crossref","unstructured":"Rosenberg R, Maak M, Simon I et al Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients. ASCO Meeting Abstracts 29:358","DOI":"10.1200\/jco.2011.29.4_suppl.358"},{"key":"856_CR30","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2011.35.4498","volume":"29","author":"RD Kennedy","year":"2011","unstructured":"Kennedy RD, Bylesjo M, Kerr P et al (2011) Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol 29:4620\u20134626","journal-title":"J Clin Oncol"},{"key":"856_CR31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","volume":"28","author":"AD Roth","year":"2010","unstructured":"Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466\u2013474","journal-title":"J Clin Oncol"},{"key":"856_CR32","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408\u20131417","journal-title":"N Engl J Med"},{"key":"856_CR33","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Cutsem Van","year":"2011","unstructured":"Van Cutsem E, Kohne CH, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011\u20132019","journal-title":"J Clin Oncol"},{"key":"856_CR34","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","volume":"22","author":"C Bokemeyer","year":"2011","unstructured":"Bokemeyer C, Bondarenko I, Hartmann JT et al (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22:1535\u20131546","journal-title":"Ann Oncol"},{"key":"856_CR35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663\u2013671","journal-title":"J Clin Oncol"},{"key":"856_CR36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","volume":"11","author":"G Folprecht","year":"2010","unstructured":"Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38\u201347","journal-title":"Lancet Oncol"},{"key":"856_CR37","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","volume":"377","author":"TS Maughan","year":"2011","unstructured":"Maughan TS, Adams RA, Smith CG et al (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377:2103\u20132114","journal-title":"Lancet"},{"key":"856_CR38","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","volume":"11","author":"W Roock De","year":"2010","unstructured":"De Roock W, Claes B, Bernasconi D et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753\u2013762","journal-title":"Lancet Oncol"},{"key":"856_CR39","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1001\/jama.2010.1535","volume":"304","author":"W Roock De","year":"2010","unstructured":"De Roock W, Jonker DJ, Di Nicolantonio F et al (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812\u20131820","journal-title":"JAMA"},{"key":"856_CR40","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697\u20134705","journal-title":"J Clin Oncol"},{"key":"856_CR41","first-page":"3510","volume":"29","author":"J Douillard","year":"2011","unstructured":"Douillard J, Siena S, Cassidy J et al (2011) Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC). ASCO Meet Abstr 29:3510","journal-title":"ASCO Meet Abstr"},{"key":"856_CR42","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/bjc.2011.26","volume":"104","author":"N Knijn","year":"2011","unstructured":"Knijn N, Mekenkamp LJ, Klomp M et al (2011) KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104:1020\u20131026","journal-title":"Br J Cancer"},{"key":"856_CR43","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1200\/JCO.2009.22.4295","volume":"27","author":"SD Richman","year":"2009","unstructured":"Richman SD, Seymour MT, Chambers P et al (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27:5931\u20135937","journal-title":"J Clin Oncol"},{"key":"856_CR44","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1200\/JCO.2006.10.5437","volume":"25","author":"S Khambata-Ford","year":"2007","unstructured":"Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230\u20133237","journal-title":"J Clin Oncol"},{"key":"856_CR45","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/annonc\/mdp336","volume":"21","author":"KL Spindler","year":"2010","unstructured":"Spindler KL, Andersen RF, Jensen LH et al (2010) EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. Ann Oncol 21:535\u2013539","journal-title":"Ann Oncol"},{"key":"856_CR46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","volume":"6","author":"M Moroni","year":"2005","unstructured":"Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279\u2013286","journal-title":"Lancet Oncol"},{"key":"856_CR47","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1200\/JCO.2008.21.6796","volume":"27","author":"P Laurent-Puig","year":"2009","unstructured":"Laurent-Puig P, Cayre A, Manceau G et al (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924\u20135930","journal-title":"J Clin Oncol"},{"key":"856_CR48","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/sj.bjc.6605471","volume":"102","author":"FV Negri","year":"2010","unstructured":"Negri FV, Bozzetti C, Lagrasta CA et al (2010) PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102:162\u2013164","journal-title":"Br J Cancer"},{"key":"856_CR49","unstructured":"(2009) Libro Blanco de la Anatom\u00eda Patol\u00f3gica en Espa\u00f1a. Recursos, calidad e impacto de la Patolog\u00eda en Espa\u00f1a., 2nd edn. ISBN 13:978-84-692-1562-3"},{"key":"856_CR50","unstructured":"Bosman FT, Organization WH, Cancer IAfRo (2010) WHO classification of tumours of the digestive system. In: Fred T, Bosman et al. (eds) 4th edn. IARC Press, Lyon"},{"key":"856_CR51","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmoldx.2011.03.002","volume":"13","author":"K Balschun","year":"2011","unstructured":"Balschun K, Haag J, Wenke AK et al (2011) KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. J Mol Diagn 13:436\u2013445","journal-title":"J Mol Diagn"},{"key":"856_CR52","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00280-010-1298-9","volume":"66","author":"M Bouchahda","year":"2010","unstructured":"Bouchahda M, Karaboue A, Saffroy R et al (2010) Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 66:605\u2013609","journal-title":"Cancer Chemother Pharmacol"},{"key":"856_CR53","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1245\/s10434-009-0864-z","volume":"17","author":"A Italiano","year":"2010","unstructured":"Italiano A, Hostein I, Soubeyran I et al (2010) KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 17:1429\u20131434","journal-title":"Ann Surg Oncol"},{"key":"856_CR54","first-page":"4229","volume":"30","author":"P Mariani","year":"2010","unstructured":"Mariani P, Lae M, Degeorges A et al (2010) Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Res 30:4229\u20134235","journal-title":"Anticancer Res"},{"key":"856_CR55","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Losa J, Sanz J, Landolfi S et al (2012) Recomendaciones para la determinaci\u00f3n de mutaciones de K-RAS en c\u00e1ncer de colon. Rev Esp Patol (In press)","DOI":"10.1016\/j.patol.2011.11.005"},{"key":"856_CR56","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M","volume":"92","author":"NS Goldstein","year":"2001","unstructured":"Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92:1331\u20131346","journal-title":"Cancer"},{"key":"856_CR57","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/00313020902884477","volume":"41","author":"C Hemmings","year":"2009","unstructured":"Hemmings C, Broomfield A, Bean E et al (2009) Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH. Pathology 41:356\u2013360","journal-title":"Pathology"},{"key":"856_CR58","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.bjc.6605473","volume":"102","author":"RL Rego","year":"2010","unstructured":"Rego RL, Foster NR, Smyrk TC et al (2010) Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 102:165\u2013172","journal-title":"Br J Cancer"},{"key":"856_CR59","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12094-008-0147-3","volume":"10","author":"J Castro-Carpeno de","year":"2008","unstructured":"de Castro-Carpeno J, Belda-Iniesta C, Casado Saenz E et al (2008) EGFR and colon cancer: a clinical view. Clin Transl Oncol 10:6\u201313","journal-title":"Clin Transl Oncol"},{"key":"856_CR60","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/sj.bjc.6604009","volume":"97","author":"M Frattini","year":"2007","unstructured":"Frattini M, Saletti P, Romagnani E et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139\u20131145","journal-title":"Br J Cancer"},{"key":"856_CR61","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1158\/0008-5472.CAN-07-5659","volume":"68","author":"M Jhawer","year":"2008","unstructured":"Jhawer M, Goel S, Wilson AJ et al (2008) PIK3CA mutation\/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68:1953\u20131961","journal-title":"Cancer Res"},{"key":"856_CR62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdn541","volume":"20","author":"F Perrone","year":"2009","unstructured":"Perrone F, Lampis A, Orsenigo M et al (2009) PI3KCA\/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20:84\u201390","journal-title":"Ann Oncol"},{"key":"856_CR63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2559.2009.03468.x","volume":"56","author":"KS Jang","year":"2010","unstructured":"Jang KS, Song YS, Jang SH et al (2010) Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology 56:229\u2013239","journal-title":"Histopathology"},{"key":"856_CR64","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejso.2010.12.003","volume":"37","author":"CP Hsu","year":"2011","unstructured":"Hsu CP, Kao TY, Chang WL et al (2011) Clinical significance of tumor suppressor PTEN in colorectal carcinoma. Eur J Surg Oncol 37:140\u2013147","journal-title":"Eur J Surg Oncol"},{"key":"856_CR65","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAI.0b013e3181f1da13","volume":"19","author":"Z Sangale","year":"2011","unstructured":"Sangale Z, Prass C, Carlson A et al (2011) A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol 19:173\u2013183","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"856_CR66","doi-asserted-by":"crossref","unstructured":"Mao C, Yang ZY, Hu XF et al (2011) PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 23(6):1518\u20131525","DOI":"10.1093\/annonc\/mdr464"},{"key":"856_CR67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.anndiagpath.2007.12.001","volume":"12","author":"V Shtilbans","year":"2008","unstructured":"Shtilbans V, Wu M, Burstein DE (2008) Current overview of the role of Akt in cancer studies via applied immunohistochemistry. Ann Diagn Pathol 12:153\u2013160","journal-title":"Ann Diagn Pathol"},{"key":"856_CR68","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.5858\/133.10.1539","volume":"133","author":"MK Washington","year":"2009","unstructured":"Washington MK, Berlin J, Branton P et al (2009) Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med 133:1539\u20131551","journal-title":"Arch Pathol Lab Med"},{"key":"856_CR69","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12094-010-0490-z","volume":"12","author":"X Sanjuan","year":"2010","unstructured":"Sanjuan X, Salas A, Lloreta J et al (2010) Colorectal Cancer OncoGuia: surgical pathology report guidelines. Clin Transl Oncol 12:211\u2013213","journal-title":"Clin Transl Oncol"},{"key":"856_CR70","unstructured":"Sobin LH GMaWC (2009) TNM classification of malignant tumours. 7th edn. Wiley, New York"},{"key":"856_CR71","unstructured":"Ley 14\/2007, de 3 de Julio, de Investigaci\u00f3n Biom\u00e9dica. http:\/\/www.boe.es\/boe\/dias\/2007\/07\/04\/pdfs\/A28826-28848.pdf"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-012-0856-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-012-0856-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-012-0856-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T02:37:00Z","timestamp":1642905420000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-012-0856-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,27]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["856"],"URL":"https:\/\/doi.org\/10.1007\/s12094-012-0856-5","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,27]]}}}